KOPRAN Stock Overview
An integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Kopran Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹253.06 |
| 52 Week High | ₹292.30 |
| 52 Week Low | ₹159.70 |
| Beta | 0.51 |
| 11 Month Change | 6.44% |
| 3 Month Change | -0.075% |
| 1 Year Change | 48.77% |
| 33 Year Change | 26.31% |
| 5 Year Change | 577.54% |
| Change since IPO | 201.26% |
Recent News & Updates
Recent updates
Does Kopran (NSE:KOPRAN) Have A Healthy Balance Sheet?
Jun 12
Here's Why Kopran (NSE:KOPRAN) Has A Meaningful Debt Burden
Jan 05Here's Why Kopran (NSE:KOPRAN) Has A Meaningful Debt Burden
Jun 03Kopran's (NSE:KOPRAN) Dividend Will Be Increased To ₹3.00
Jul 14Here's Why I Think Kopran (NSE:KOPRAN) Might Deserve Your Attention Today
Nov 25Should You Be Adding Kopran (NSE:KOPRAN) To Your Watchlist Today?
Jun 10These 4 Measures Indicate That Kopran (NSE:KOPRAN) Is Using Debt Safely
Mar 21If You Had Bought Kopran (NSE:KOPRAN) Stock A Year Ago, You Could Pocket A 327% Gain Today
Feb 14Kopran Limited's (NSE:KOPRAN) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 24Is Kopran (NSE:KOPRAN) A Risky Investment?
Dec 20
Introducing Kopran (NSE:KOPRAN), The Stock That Soared 338% In The Last Year
Nov 15Kopran Limited's (NSE:KOPRAN) Stock Is Going Strong: Is the Market Following Fundamentals?
Oct 11Is Kopran (NSE:KOPRAN) Using Too Much Debt?
Sep 07Kopran Limited's (NSE:KOPRAN) Shares Not Telling The Full Story
Jul 31Calculating The Fair Value Of Kopran Limited (NSE:KOPRAN)
Jul 13Shareholder Returns
| KOPRAN | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.3% | -1.7% | -0.1% |
| 1Y | 48.8% | 50.6% | 46.3% |
Return vs Industry: KOPRAN underperformed the Indian Pharmaceuticals industry which returned 51.1% over the past year.
Return vs Market: KOPRAN exceeded the Indian Market which returned 45.3% over the past year.
Price Volatility
| KOPRAN volatility | |
|---|---|
| KOPRAN Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in IN Market | 9.5% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: KOPRAN has not had significant price volatility in the past 3 months.
Volatility Over Time: KOPRAN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 902 | Surendra Somani | www.kopran.com |
Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as topical preparations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular.
Kopran Limited Fundamentals Summary
| KOPRAN fundamental statistics | |
|---|---|
| Market cap | ₹12.19b |
| Earnings (TTM) | ₹509.56m |
| Revenue (TTM) | ₹6.15b |
23.9x
P/E Ratio2.0x
P/S RatioIs KOPRAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KOPRAN income statement (TTM) | |
|---|---|
| Revenue | ₹6.15b |
| Cost of Revenue | ₹4.02b |
| Gross Profit | ₹2.13b |
| Other Expenses | ₹1.62b |
| Earnings | ₹509.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.57 |
| Gross Margin | 34.60% |
| Net Profit Margin | 8.29% |
| Debt/Equity Ratio | 20.2% |
How did KOPRAN perform over the long term?
See historical performance and comparison